Life-extending cystic fibrosis drugs will be available on the NHS next month after a deal was struck following four years of deadlock. Manufacturer Vertex and NHS England have reached an agreement on access to all of Vertex's currently licensed cystic fibrosis (CF) medicines to all eligible patients in England.
This important agreement, reached in collaboration and partnership with NHS England and the National Institute for Health and Care Excellence (NICE), means that more than 5,000 eligible CF patients in England can be prescribed these CFTR modulators within 30 days.
Robert said: "Absolutely incredible news that a deal has been agreed to provide Orkambi and other life-saving Cystic Fibrosis drugs on the NHS.
"I will never forget meeting two constituents last year who were desperate for their young daughter to have access to this treatment - and I know this breakthrough will come as wonderful news to them and the entire CF community.
"Thank you to everyone who campaigned and negotiated to deliver this landmark deal which will benefit the lives of many."
